Picture of Arecor Therapeutics logo

AREC Arecor Therapeutics Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-4.61%
3m-22.17%
6m-32.55%
1yr-47.01%
Volume Change (%)
10d/3m+36.44%
Price vs... (%)
52w High-54.01%
50d MA-5.47%
200d MA-23%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-75.27%
Return on Equity-67.81%
Operating Margin-306.51%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Arecor Therapeutics EPS forecast chart

Profile Summary

Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.

Directors

    Last Annual
    December 31st, 2022
    Last Interim
    June 30th, 2023
    Incorporated
    April 13th, 2021
    Public Since
    June 3rd, 2021
    No. of Employees
    51
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    gb flag iconLondon Stock Exchange
    Shares in Issue
    30,626,986

    AREC Share Price Performance

    Upcoming Events for AREC

    Full Year 2024 Arecor Therapeutics PLC Earnings Release

    Arecor Therapeutics PLC Annual Shareholders Meeting

    Half Year 2025 Arecor Therapeutics PLC Earnings Release

    Similar to AREC

    Picture of 4Basebio logo

    4Basebio

    gb flag iconLondon Stock Exchange

    Picture of Allergy Therapeutics logo

    Allergy Therapeutics

    gb flag iconLondon Stock Exchange

    Picture of Avacta logo

    Avacta

    gb flag iconLondon Stock Exchange

    Picture of Batm Advanced Communications logo

    Batm Advanced Communications

    gb flag iconLondon Stock Exchange

    Picture of Bioventix logo

    Bioventix

    gb flag iconLondon Stock Exchange

    FAQ